BOULDER, Colo., February 17, 2004 -- /PRNewswire-FirstCall/ -- Encision's (Amex: ECI) electrosurgical technology has been cited in the new AORN Recommended Practices for Electrosurgery, published by the Association of periOperative Registered Nurses (AORN) in the February issue of the AORN Journal.

AORN is the professional organization of 41,000 perioperative personnel dedicated to achieving optimal outcomes for patients undergoing surgical procedures. As a part of their overall effort, AORN publishes AORN Recommended Practices providing guidance to perioperative personnel on what is believed to be an optimal level of practice.

In the new Recommended Practices for Electrosurgery, effective January 1, 2004, the AORN includes numerous references to the importance of using electrosurgical devices designed for optimal safety.

Recommended Practice I -- Personnel selecting the electrosurgical (devices) for purchase or use should make decisions based on safety features to minimize risks to patients and personnel.

• Equipment selected should include technology to detect stray current that could result in patient injury and to alert the user of this condition.
  
• During minimally invasive procedures, injuries have resulted from insulation failure and capacitive coupling. These injuries are very serious and have increased in number with the increased use of laparoscopic surgery.
  
• The use of active electrode monitoring has minimized these risks.

• Insulation failure of the laparoscopic electrode ... can cause serious patient injury.
  
• Capacitively coupled current can cause undetected burns to nearby tissue ... outside the viewing field. Serious patient injuries have resulted.
  
• Use of active electrode shielding and monitoring minimizes the risks of insulation failure and capacitive-coupling injuries.

Encision's AEM® Surgical Instruments are 'shielded and monitored' to prevent stray electrosurgical burn injuries to unintended tissue, a well-documented patient safety risk in minimally-invasive surgery. AEM Instruments incorporate 'active electrode monitoring' technology to dynamically monitor the integrity of the instruments continuously during the surgical procedure, thus helping to prevent an inadvertent patient injury.

Electrosurgery instruments are used by an estimated 85% of general surgeons in the U.S. and are considered the gold-standard tool for surgeons worldwide for cutting, coagulating and ablating tissue.

Encision Inc. designs and manufactures innovative surgical devices that allow the surgeon to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM® Surgical Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.

AORN Recommended Practices do not endorse any specific company or product; however, Encision's AEM Instruments are the only instruments on the market which incorporate a 'shielded and monitored' design to prevent the risk of stray electrosurgical burn injury from insulation failure and capacitive coupling in minimally invasive surgery.

AORN believes that a culture of safety must be created, nurtured and promoted and that leaders must take an active role in ensuring processes to maintain and improve patient safety. In 2002, AORN launched a major patient safety program called Patient Safety First, a program intended to promote dialogue, strategies and initiatives on patient safety issues. AORN's patient safety initiative is intended to advance system solutions with safety as the first priority, so that these solutions can be implemented to prevent errors and adverse events in the surgical environment.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Encision notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase revenues through the Company's distribution channels, insufficient quantity of new account conversions, insufficient cash to fund operations, scale up production to meet delivery obligations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission.